Rethinking Inhalation Drug Development

By Justin Lacombe, Ph.D., Chief Scientific Officer, and Komal Patel, Associate Director, Pharmaceutical Development, Experic

Inhalation drug delivery is rapidly expanding beyond traditional respiratory indications, driven by advances in particle engineering, excipient innovation, and device technology. Dry powder inhalers (DPIs) now offer a viable path for delivering small molecules, biologics, RNA‑based therapeutics, and even vaccines, supported by advantages in stability, manufacturability, and patient usability. As interest grows in non‑invasive systemic delivery and targeted routes to the brain, nasal and pulmonary powders are opening opportunities for faster absorption, enhanced bioavailability, and reduced dosing requirements.

These innovations also introduce new formulation and manufacturing challenges, from controlling particle attributes to ensuring device compatibility and achieving scalable, compliant production. Developers must navigate limited excipient options, evolving regulatory expectations, and the complexities of aerodynamic particle size distribution — factors that demand deep technical expertise and disciplined process design.

The full asset offers a detailed look at the scientific and operational considerations shaping next‑generation DPI development and highlights strategies to reduce risk, strengthen performance, and prepare inhaled therapies for clinical and commercial success.